LimiFlex DST is designed as an alternative to spinal fusion, according to a July 13 news release. It is used for grade 1 degenerative spondylolisthesis patients with spinal stenosis.
The company said it is on track to submit its PMA Module III in 2022. LimiFlex already has the FDA’s Breakthrough Device Designation.
“We believe LimiFlex is an exciting advancement in stabilization surgery that uses a completely different concept for durable motion preservation to better meet the pressing need for improved outcomes with a lower cost of care,” Richard Treadwell, president and CEO of Empirical Spine, said in the release.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.